Abstract |
The Tigecycline Evaluation and Surveillance Trial is a global surveillance study established in 2004 to monitor the activity of tigecycline, a new glycylcycline, and several comparators against an array of important Gram-positive and Gram-negative pathogens. In this study, we examined 1591 isolates of Acinetobacter from blood samples collected from 352 centers globally between 2004 and 2008. Tigecycline showed an MIC(90) (1 microg/mL) globally, with a maximum regional value of 4 microg/mL (Middle East) reported. Antimicrobial susceptibility was notably higher among nonintensive care unit (non-ICU) isolates than isolates collected from ICUs. Carbapenem-resistant Acinetobacter were more prevalent in the Middle East, Latin America, and Asia/Pacific rim than in Europe or North America. Tigecycline creep was noted between 2004 and 2007, corresponding closely to changes in MIC(90).
|
Authors | Yun F Wayne Wang, Michael J Dowzicky |
Journal | Diagnostic microbiology and infectious disease
(Diagn Microbiol Infect Dis)
Vol. 68
Issue 1
Pg. 73-9
(Sep 2010)
ISSN: 1879-0070 [Electronic] United States |
PMID | 20727474
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Culture Media
- Tigecycline
- Minocycline
|
Topics |
- Acinetobacter
(classification, drug effects, isolation & purification)
- Anti-Bacterial Agents
(pharmacology)
- Asia
(epidemiology)
- Bacteremia
(epidemiology, microbiology)
- Blood
(microbiology)
- Culture Media
- Drug Resistance, Bacterial
- Europe
(epidemiology)
- Humans
- Intensive Care Units
- Latin America
(epidemiology)
- Microbial Sensitivity Tests
(standards)
- Minocycline
(analogs & derivatives, pharmacology)
- North America
(epidemiology)
- Population Surveillance
(methods)
- Tigecycline
|